MARKET IMPACT SURVEY - COVID-19 & LOOMING RECESSION
Timely market intelligence is paramount in these uncertain times!
We launched an impact survey to update this project with timely insights during 2020. Update frequency will depend upon evolving market conditions and executive opinions. Our participants are executives driving strategy, marketing, sales and product management at competitive companies worldwide. All updates during the rest of the year are complimentary to clients!
Global Autoinjectors Market to Reach $118.6 Billion by 2027
Amid the COVID-19 crisis, the global market for Autoinjectors estimated at US$35.1 Billion in the year 2020, is projected to reach a revised size of US$118.6 Billion by 2027, growing at a CAGR of 19% over the analysis period 2020-2027. Rheumatoid Arthritis, one of the segments analyzed in the report, is projected to record a 20.8% CAGR and reach US$43.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Multiple Sclerosis segment is readjusted to a revised 18.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $9.5 Billion, While China is Forecast to Grow at 24.1% CAGR
The Autoinjectors market in the U.S. is estimated at US$9.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$28 Billion by the year 2027 trailing a CAGR of 24.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.7% and 17.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.
Anaphylaxis Segment to Record 18.1% CAGR
In the global Anaphylaxis segment, USA, Canada, Japan, China and Europe will drive the 17.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.4 Billion in the year 2020 will reach a projected size of US$13.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$17.3 Billion by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period. We bring years of research experience to this 4th edition of our report. The 189-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, - AbbVie, Inc.
- Amgen, Inc.
- Antares Pharma, Inc.
- Becton, Dickinson and Company
- Consort Medical PLC
- Eli Lilly and Company
- Haselmeier GmbH
- Mylan NV
- Owen Mumford Ltd.
- SHL Group
- Teva Pharmaceutical Industries Ltd.
- Ypsomed AG